By Robert Preidt
FRIDAY, Nov. 20, 2020 (HealthDay Information) — The antiviral drug remdesivir isn’t really helpful for hospitalized COVID-19 sufferers as a result of there is no proof that it reduces their want for air flow or improves their possibilities of survival, a World Well being Group panel mentioned Thursday.
Remdesivir is thought to be a possible remedy for extreme COVID-19 and is used to deal with hospitalized sufferers, however there’s uncertainty about its effectiveness. However, the U.S. Meals and Drug Administration accredited the drug to deal with hospitalized COVID-19 sufferers in October.
Within the new evaluation, the WHO panel of consultants analyzed information from 4 worldwide randomized trials that assessed a number of remedies for COVID-19 and included greater than 7,000 hospitalized COVID-19 sufferers.
The panel — which included 4 individuals who’ve had COVID-19 — concluded that remdesivir has no significant affect on the chance of loss of life or every other vital affected person outcomes, comparable to the necessity for mechanical air flow or how lengthy it takes for his or her situation to enhance.
The outcomes of the trials do not show that remdesivir has no profit. As a substitute, they supply no proof that the drug improves affected person outcomes, the panel defined in an article printed Nov. 19 within the BMJmedical journal.
Nonetheless, given the chance of serious hurt, the comparatively excessive value, and the calls for on well being care employees (remdesivir should be given intravenously), their suggestion is acceptable, the panel mentioned.
The panel additionally mentioned they assist continued enrollment into trials evaluating the usage of remdesivir in COVID-19 sufferers, particularly to offer extra dependable proof for particular teams of sufferers.
The long run use of remdesivir in treating COVID-19 sufferers is unclear, provided that it is unlikely to be the lifesaving drug many have hoped for, American journalist Jeremy Hsu wrote in a linked article within the journal.
He additionally famous that various remedies — comparable to the cheap and extensively out there corticosteroid dexamethasone, which has been proven to scale back loss of life danger in severely in poor health COVID-19 sufferers — are actually a part of the discussions about remdesivir’s value as a COVID-19 remedy.
“It is turn out to be clear that remdesivir, at greatest, has a marginal profit if any on scientific enchancment,” mentioned Dr. Amesh Adalja, a senior scholar on the Johns Hopkins Heart for Well being Safety in Baltimore. “It’s not stunning, subsequently, that the WHO guideline committee doesn’t assist its use, underscoring the necessity for higher remedies that extra meaningfully affect affected person outcomes.”
For extra on remedies for extreme COVID-19, go to the U.S. Facilities for Illness Management and Prevention.
SOURCES: BMJ, information launch, Nov. 19, 2020; Amesh Adalja, MD, senior scholar, Johns Hopkins Heart for Well being Safety, Baltimore